Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kowa Research Institute, Inc.
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Is at least 18 years old at the screening visit (Visit 1).

• Has a diagnosis of FECD at Visit 1.

• Meet all other inclusion criteria outlined in clinical study protocol.

Exclusion Criteria:

• Has a study eye with a history of cataract surgery within 90 days of Visit 1.

• Has a study eye with a history of any previous ocular surgery other than for cataract.

• Meet any other exclusion criteria outlined in clinical study protocol.